Interview with Delphine Perridy, Chief Commercial Officer, Envirotainer

Update : 6th June, 2024

In this exclusive interview, Envirotainer's Chief Commercial Officer, Delphine Perridy, and Cold Chain Platform's CEO, Linda Kim, discuss the evolving landscape of cold chain logistics in the pharmaceutical industry.

They explore how Envirotainer is leading in addressing trends such as personalized medicine and advanced therapies, overcoming unforeseen disruptions, and leveraging cutting-edge technologies to enhance supply chain efficiency. Delphine also shares insights into Envirotainer’s sustainability initiatives and the strategic acquisition of va-Q-tec, aimed at enhancing global healthcare delivery.

Linda Kim, CEO, CCP (Left) and Delphine Perridy, CCO, Envirotainer (Right)

1. Given your extensive experience in the life science industry, what are the major trends you currently see influencing the global pharmaceutical sector? And, how is Envirotainer adapting its strategies to address these trends?

The life sciences industry continues to grow despite a challenging year in 2023. Advances in personalised medicine and cell & gene therapies have increased the need for strict temperature control, putting pressure on the cold chain to minimise degradation risks.

In response, the cold chain is getting colder (product temperatures), smaller (personalised medicines) and more global (difficult/remote deliveries to patients). New technologies and AI are accelerating drug development and bringing much-needed medicines to patients faster.

Additionally, stricter regulatory requirements for serialisation and tracking are creating a need for greater transparency and control within the supply chain. The use of data analytics that can predict potential cold chain disruptions, allows for proactive interventions and cost savings.

As these trends continue to develop, we are expanding our solution portfolio to maximise the access to and safety of therapies and improving our digital services to provide real-time data and better visibility and reach patients in an optimal condition.

2. The logistics industry, particularly the pharmaceutical cold chain sector, faces numerous unforeseen disruptions. How is Envirotainer evolving its operations to maintain reliability and efficiency in the face of such challenges?

Envirotainer specialises in air freight solutions for the pharmaceutical sector, where preparing for unforeseen disruptions is a constant challenge. We address issues like extreme weather, geopolitical instability and social unrest with robust contingency planning and an extensive global network. With service stations in over 100 countries and access to 300 airports and more than 3,300 pharma trade lanes, we are well-prepared to adapt as needed.

To handle climate changes, we use advanced cooling technologies and real-time monitoring to maintain stable temperatures, despite fluctuating external conditions. We also apply machine learning to analyse shipment data, allowing us to identify and address potential issues early.

Our goal is to keep delivering critical pharmaceuticals reliably and efficiently to wherever they need to be, no matter what challenges the future may hold.

3. With advancements in technology, particularly in data analytics and digital tools, how is Envirotainer leveraging these technologies to improve visibility and manage risks more effectively?

Data is invaluable in the transportation of temperature-sensitive pharmaceuticals. We collect comprehensive data throughout the entire shipment duration using IoT-enabled containers and share these with our customers in real-time, where possible.

Armed with information such as shipment reports and real-time monitoring tools, customers can actively watch over their shipments, set alerts and quickly respond to any situation should it occur – reducing the risk of losing products due to incorrect temperatures or mishandling.

By analysing both historical and real-time data, we can predict and prevent potential problems. We can advise on how routes can be adjusted, and operational procedures can be updated to minimise risks. This helps us maintain high service quality and support the pharmaceutical industry’s need for reliable and efficient cold chain solutions.

Envirotainer Releye® RLP Container

4. Sustainability is a critical focus for both pharmaceutical and logistics industries. Can you tell us the initiatives Envirotainer has implemented to reduce emissions and enhance sustainability?

We use detailed data and transparent reporting to not just track, but actively reduce our carbon emissions. Our approach is guided by Science Based Targets, which help us keep our environmental impact in line with the Paris Agreement’s goals.

We are particularly proud of being the only provider in our industry committed to a long-term net-zero target. Our products, like the RAP e2 and Releye RAP containers, are designed to be as lightweight and efficient as possible, significantly reducing carbon emissions. They’re reusable too, which helps cut down on waste.

We are constantly innovating, using everything from life cycle assessments to CO2 calculation tools developed with climate experts, making sure our solutions are as sustainable as they can be. Plus, our commitment to the UN Global Compact shows we’re serious about upholding global sustainability standards. In simple terms, we’re working hard to make sure our operations help, not hurt, our planet.

5. Regarding Envirotainer’s acquisition of va-Q-tec, how does this strategic move position Envirotainer to better serve global healthcare needs, and what improvements can your customers expect from this integration?

Our acquisition of va-Q-tec is a key part of our mission to deliver life-saving medicines safely and efficiently globally. Combining our active cooling solutions with va-Q-tec’s advanced passive technology will enable us to meet all needs of our customers across temperature ranges, shipment sizes and stages of the pharmaceutical life cycle.

With a complete portfolio of cold chain solutions, we will be able to handle shipments for clinical trials, active product ingredients and finished medicines for commercial deliveries.

This merger, set to complete later this year, also expands our network of service stations. This means we will be in an even better position to meet the growing global demand for reliable, temperature-controlled pharmaceutical transport with the largest network in the industry.


About Delphine Perridy

Chief Commercial Officer, Envirotainer

Delphine is the Chief Commercial Officer at Envirotainer, responsible for defining and executing the global commercial strategy. She brings 20+ years of experience acquired in the life sciences industry. She has experience working in EMEA, APAC & Americas, setting up and growing business units.

Before joining Envirotainer she was VP, FSP Global Sales for IQVIA. She has also worked for IMS Health, Cegedim and AXA in various global leadership roles.

Delphine holds a master’s degree in business & management acquired at EM Normandie with HEC Entrepreneurs in France.

About Envirotainer

Envirotainer is the specialist in secure cold chain solutions for intercontinental transport of pharmaceuticals. The company develops, manufactures and offers leasing of innovative container solutions and dewars for cryogenic shipping, including validation, support and service, for pharma products that require a controlled environment. Thanks to a truly global presence with the world’s largest active container fleet, the most extensive network and more than 35 years of industry expertise, Envirotainer is able to meet the customers’ need for innovative and reliable solutions - available from any location to any destination. The company operates through an open, global network of airlines and forwarders and the headquarters is located outside of Stockholm, Sweden. For more information, please visit www.envirotainer.com


This article complies with our Editorial Policy

Follow CCP